



Universiteit  
Leiden  
The Netherlands

## **Imaging functional brain connectivity : pharmacological modulation, aging and Alzheimer's disease**

Klaassens, B.L.

### **Citation**

Klaassens, B. L. (2018, September 6). *Imaging functional brain connectivity : pharmacological modulation, aging and Alzheimer's disease*. Retrieved from <https://hdl.handle.net/1887/65052>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/65052>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/65052> holds various files of this Leiden University dissertation.

**Author:** Klaassens, B.L.

**Title:** Imaging functional brain connectivity : pharmacological modulation, aging and Alzheimer's disease

**Issue Date:** 2018-09-06

# Chapter 3

## Time related effects on functional brain connectivity after serotonergic and cholinergic neuromodulation

*Published in Human Brain Mapping 2017; 38(1):308-325*

**Bernadet L. Klaassens<sup>a,b,c,d</sup>, Serge A.R.B. Rombouts<sup>a,b,c</sup>, Anderson M. Winkler<sup>e</sup>, Helene C. van Gorsel<sup>b,c,d</sup>, Jeroen van der Grond<sup>b</sup>, Joop M.A. van Gerven<sup>d</sup>**

<sup>a</sup>Leiden University, Institute of Psychology, Leiden, the Netherlands, <sup>b</sup>Leiden University Medical Center, Department of Radiology, Leiden, the Netherlands, <sup>c</sup>Leiden University, Leiden Institute for Brain and Cognition, Leiden, the Netherlands, <sup>d</sup>Centre for Human Drug Research, Leiden, the Netherlands, <sup>e</sup>Oxford University, Oxford Centre for Functional MRI of the Brain, Oxford, United Kingdom

**ABSTRACT**

Psychopharmacological research, if properly designed, may offer insight into both timing and area of effect, increasing our understanding of the brain's neurotransmitter systems. For that purpose, the acute influence of the selective serotonin reuptake inhibitor citalopram (30 mg) and the acetylcholinesterase inhibitor galantamine (8 mg) was repeatedly measured in 12 healthy young volunteers with resting state functional magnetic resonance imaging (RS-fMRI). Eighteen RS-fMRI scans were acquired per subject during this randomized, double blind, placebo-controlled, crossover study. Within-group comparisons of voxelwise functional connectivity with 10 functional networks were examined ( $p < 0.05$ , FWE-corrected) using a non-parametric multivariate approach with cerebrospinal fluid, white matter, heart rate and baseline measurements as covariates. Although both compounds did not change cognitive performance on several tests, significant effects were found on connectivity with multiple resting state networks. Serotonergic stimulation primarily reduced connectivity with the sensorimotor network and structures that are related to self-referential mechanisms, whereas galantamine affected networks and regions that are more involved in learning, memory, and visual perception and processing. These results are consistent with the serotonergic and cholinergic trajectories and their functional relevance. In addition, this study demonstrates the power of using repeated measures after drug administration, which offers the chance to explore both combined and time specific effects.

## INTRODUCTION

Drugs acting on serotonin (5-hydroxytryptamine; 5-HT) and acetylcholine (ACh) are known for their regulating influence on behavior and cognition. Selective serotonin reuptake inhibitors (SSRIs) are accepted for their mood altering properties and usually prescribed to treat depression and anxiety disorders [50, 109]. Acetylcholinesterase inhibitors (AChEIs) are found to be beneficial in neurodegenerative disorders (Alzheimer's disease (AD), dementia with Lewy bodies and Parkinson's disease) due to their effect on attention, learning and memory [63, 189].

The brain's serotonergic axonal pathways originate in the midbrain's medial and dorsal raphe nuclei. In the central nervous system (CNS), a particularly high density of 5-HT receptors is observed in the cerebral cortex, limbic structures, basal ganglia and brain stem regions [47, 190]. For ACh, the major source is the basal forebrain, with fibers diffusing to the cortex, amygdala and hippocampus [59]. The finding that specific neurotransmitters like 5-HT and ACh also act as neuromodulators, has led to the formation of distributed computational network models [191-193]. Consequently, studies of cholinergic or serotonergic drug effects also need to consider their extensive modulatory effects [194]. This is possible with resting state functional magnetic resonance imaging (RS-fMRI) in the context of pharmacological stimulation [7, 195].

Evidence is growing on the sensitivity of resting state networks, consisting of regions with coherent blood-oxygen-level-dependent fluctuations, to pharmacological challenges [76, 78-81]. These networks have consistently been found in healthy and clinical conditions, and are related to specific functions of the brain (i.e. motor, auditory, visual, emotional and executive function) [9, 10, 196, 197]. Disruptions of functional networks have been demonstrated in both depressed and demented patients, especially for the default mode network (DMN) [20, 88, 198]. Several studies point to normalization of DMN connectivity in depression after SSRI administration [82, 85-87]. Yet, there is also proof of more extensive effects of SSRIs on brain connectivity [83, 199]. In AD patients, cholinergic stimulation induces alterations in connectivity for DMN regions [89-91], as well as networks involved in attention, control and salience processing [200].

Characteristically, neuromodulators support the processing of sensory information, coordination of motor output and higher order cognitive functioning [201-203]. In line with the diverse and widespread patterns of effect of both transmitters we investigated the direct influence of the SSRI citalopram 30 mg and the AChEI galantamine 8 mg on various brain networks. Both RS-fMRI and functional (cognitive and neuroendocrine) responses were examined in 12 healthy young volunteers in a repeated measures fashion. Galantamine was hypothesized to mainly affect connectivity with brain structures that are involved in learning and memory mechanisms. Based on our previous study with the SSRI sertraline 75 mg, we expected to see widespread decreases in connectivity immediately after citalopram administration in the absence of cognitive change.

## METHOD


### Subjects

Twelve healthy young volunteers (mean age  $22.1 \pm 2.7$ , range 18-27; gender ratio 1:1, BMI 21-28 kg/m<sup>2</sup>) were recruited to participate in the study. All subjects underwent a thorough medical screening at the Centre for Human Drug Research (CHDR) to investigate whether they met the inclusion and exclusion criteria. They had a normal history of physical and mental health and were able to refrain from using nicotine and caffeine during study days. Exclusion criteria included positive drug or alcohol screen on study days, regular excessive consumption of alcohol (>4 units/day), caffeine (>6 units/day) or cigarettes (>5 cigarettes/day), use of concomitant medication 2 weeks prior to study participation and involvement in an investigational drug trial 3 months prior to administration. The study was approved by the medical ethics committee of the Leiden University Medical Center (LUMC) and the scientific review board of the CHDR. Written informed consent was obtained from each subject prior to study participation.

### Study design

This was a single center, double blind, placebo-controlled, crossover study with citalopram 30 mg and galantamine 8 mg. Each subject received citalopram, galantamine and placebo on three different occasions with a washout period in between of at least 7 days. Citalopram has an average time point of maximum concentration ( $T_{max}$ ) of 2-4 h, with a half-life ( $T_{1/2}$ ) of 36 h. For galantamine,  $T_{max} = 1-2$  h and  $T_{1/2} = 7-8$  h. To correct for the different pharmacokinetic (PK) profiles of the compounds, citalopram 20 mg was administered at  $T = 0$  h, followed by a second dose of 10 mg at  $T = 1$  h (if the first dose was tolerated and subjects did not become too nauseous). Galantamine was given as a single 8 mg dose at  $T = 2$  h. Blinding was maintained by concomitant administration of double-dummy placebo's at all three time points. All subjects also received an unblinded dose of granisetron 2 mg at  $T = -0.5$  h, to prevent the most common drug-induced adverse effects of nausea and vomiting.

Six RS-fMRI scans were acquired during study days, two at baseline and four after administering citalopram, galantamine or placebo (at  $T = 2.5, 3.5, 4.5$  and 6 h post dosing). Each scan was followed by performance of computerized cognitive tasks (taken twice at baseline) on the NeuroCart® test battery, developed by the CHDR for quantifying pharmacological effects on the CNS [167, 204, 205]. By including multiple measurements during the  $T_{max}$  interval, this repeated measures profile increases the statistical power of the analysis and allows for identification of time related effects, associated with changing serum concentrations. Nine blood samples were taken during the course of the day to define the PK profile of citalopram, citalopram's active metabolite desmethylcitalopram, galantamine and concentrations of cortisol and prolactin [182, 206]. An overview of the study design is provided in Figure 3.1.



**Figure 3.1. Schematic overview of a study day.** Each subject received citalopram, galantamine and placebo on three different days. At baseline, two RS-fMRI scans were acquired, followed by the NeuroCart® CNS test battery. After drug administration, four more RS-fMRI scans were acquired at time points  $T = 2.5, 3.5, 4.5$  and  $6$  h post dosing, each time followed by the NeuroCart® test battery. During the day, nine blood samples were taken to measure the concentrations of citalopram, desmethylcitalopram, galantamine, cortisol and prolactin. On each study day there were three moments of administration. The second administration only took place when subjects tolerated the first dose well (did not vomit or feel too nauseous):

Galantamine study day:	$T = 0$ ) placebo	$T = 1$ ) placebo	$T = 2$ ) galantamine 8 mg
Citalopram study day:	$T = 0$ ) citalopram 20 mg	$T = 1$ ) citalopram 10 mg	$T = 2$ ) placebo
Placebo study day:	$T = 0$ ) placebo	$T = 1$ ) placebo	$T = 2$ ) placebo

## Blood sampling

### *Pharmacokinetics*

Blood samples were collected in 4 mL EDTA plasma tubes at baseline and 1, 2, 2.5, 3, 3.5, 4.5 and 6 h post dosing, centrifuged (2000  $g$  for 10 min) and stored at  $-40^{\circ}\text{C}$  until analysis with liquid chromatography-tandem mass spectrometry (LC-MS/MS). PK parameters for citalopram, galantamine and citalopram's active metabolite desmethylcitalopram were calculated using a non-compartmental analysis. Maximum plasma concentrations ( $C_{\text{max}}$ ) and time of  $C_{\text{max}}$  ( $T_{\text{max}}$ ) were obtained directly from the plasma concentration data. The area under the plasma concentration vs. time curve was calculated from time zero to the time of the last quantifiable measured plasma concentration, which is equal to the last blood sample of the study day ( $\text{AUC}_{0-\text{last}}$ ). The calculated PK parameters were not used for further analysis but investigated to validate the choice of time points of measurements.

### *Neuroendocrine variables*

Blood samples were also obtained to determine cortisol and prolactin concentrations. Serum samples were taken in a 3.5 mL gel tube at baseline (twice) and 1, 2, 2.5, 3.5, 4.5 and 6 h post dosing, centrifuged (2000  $g$  for 10 min) and stored at  $-40^{\circ}\text{C}$  until analysis. Serum concentrations were quantitatively determined with electrochemiluminescence immunoassay. Cortisol and prolactin concentrations were subsequently used for statistical analysis using a mixed effects model with treatment, time, visit and treatment by time as fixed effects, subject, subject by treatment and subject by time as random effects and the average of the period baseline (pre-dose) values as covariate (SAS for Windows V9.4; SAS Institute, Inc., Cary, NC).

### **NeuroCart® test battery**

Each RS-fMRI scan was followed by functional CNS measures outside the scanner using the computerized NeuroCart® test battery measuring alertness, mood and calmness (Visual Analogue Scales (VAS) Bond & Lader), nausea (VAS Nausea), vigilance and visual motor performance (Adaptive Tracking task), reaction time (Simple Reaction Time task), attention, short-term memory, psychomotor speed, task switching and inhibition (Symbol Digit Substitution Test and Stroop task), working memory (N-back task) and memory imprinting and retrieval (Visual Verbal Learning Test) [95-103]. The Visual Verbal Learning Test was only performed once during each day (at 3 and 4 h post dosing) as the test itself consists of different trials (imprinting and retrieval). Duration of each series of NeuroCart® brain function tests was approximately 20 min. To minimize learning effects, training for the NeuroCart® tasks occurred during the screening visit within 3 weeks prior to the first study day.

### **Analysis**

All within period repeatedly measured CNS endpoints were analyzed using a mixed effects model with treatment, time, visit and treatment by time as fixed effects, subject, subject by treatment and subject by time as random effects and the average of the period baseline (pre-dose) values as covariate (SAS for Windows V9.4; SAS Institute, Inc., Cary, NC). As data of the Simple Reaction Time task were not normally distributed, these data were log-transformed before analysis and back transformed after analysis. The data of the Visual Verbal Learning test were analyzed using a mixed effects model with treatment and visit as fixed effects and subject as random effect. Treatment effects were considered significant at  $p < 0.05$  (uncorrected).

### **Imaging**

Scanning was performed at the LUMC on a Philips 3.0 Tesla Achieva MRI scanner (Philips Medical System, Best, The Netherlands) using a 32-channel head coil. During the RS-fMRI scans, all subjects were asked to close their eyes while staying awake. They were also instructed not to move their head during the scan. Instructions were given prior to each scan on all study days. T1-weighted anatomical images were acquired once per visit. To facilitate registration to the anatomical image, each RS-fMRI scan was followed by a high-resolution T2\*-weighted echo-planar scan. Duration was approximately 8 min for the RS-fMRI scan, 5 min for the anatomical scan and 30 s for the high-resolution scan. Heart rate signals were recorded during each scan.

RS-fMRI data were obtained with T2\*-weighted echo-planar imaging (EPI) with the following scan parameters: 220 whole brain volumes, repetition time (TR) = 2180 ms; echo time (TE) = 30 ms; flip angle = 85°; field-of-view (FOV) = 220 x 220 x 130 mm; in-plane voxel resolution = 3.44 x 3.44 mm, slice thickness = 3.44 mm, including 10% interslice gap. The next parameters were used to collect T1-weighted anatomical images: TR = 9.7 ms; TE = 4.6 ms; flip angle = 8°; FOV = 224 x 177



x 168 mm; in-plane voxel resolution = 1.17 x 1.17 mm; slice thickness = 1.2 mm. Parameters of high-resolution T2\*-weighted EPI scans were set to: TR = 2200 ms; TE = 30 ms; flip angle = 80°; FOV = 220 x 220 x 168 mm; in-plane voxel resolution = 1.96 x 1.96 mm; slice thickness = 2.0 mm.

### *Analysis*

All analyses were performed using the Functional Magnetic Resonance Imaging of the Brain (FMRIB) Software Library (FSL, Oxford, United Kingdom) version 5.0.7 [119-121]. Each individual functional EPI image was inspected, brain-extracted and corrected for geometrical displacements due to head movement with linear (affine) image registration [122, 123]. Images were spatially smoothed with a 6 mm full-width half-maximum Gaussian kernel and co-registered with the brain extracted high resolution T2\*-weighted EPI scans (with 6 degrees of freedom) and T1 weighted images (using the Boundary-Based-Registration method) [122, 124]. The T1-weighted scans were non-linearly registered to the MNI 152 standard space (the Montreal Neurological Institute, Montreal, QC, Canada) using FMRIB's Non-linear Image Registration Tool. Registration parameters were estimated on non-smoothed data to transform fMRI scans into standard space. Automatic Removal of Motion Artifacts based on Independent Component Analysis (ICA-AROMA vs0.3-beta) was used to detect and remove motion related artifacts. ICA decomposes the data into independent components that are either noise related or pertain to functional networks. ICA-AROMA attempts to identify noise components by investigating its temporal and spatial properties and removes these components from the data that are classified as motion related. Registration was thereafter applied on the denoised functional data with registration parameters as derived from non-smoothed data. As recommended, high pass temporal filtering (with a high pass filter of 150 s) was applied after denoising the fMRI data with ICA-AROMA [207, 208].

RS-fMRI networks were thereafter extracted from each individual denoised RS-fMRI dataset (12 subjects x 3 days x 6 scans = 216 datasets) applying a dual regression analysis [36, 125] based on 10 predefined standard network templates as used in our previous research [199]. Confound regressors of time series from white matter (measured from the center of the corpus callosum) and cerebrospinal fluid (measured from the center of lateral ventricles) were included in this analysis to account for non-neuronal signal fluctuations [126]. The 10 standard templates have previously been identified using a data-driven approach [10] and comprise the following networks: three visual networks (consisting of medial, occipital pole, and lateral visual areas), DMN (medial parietal (precuneus and posterior cingulate), bilateral inferior-lateral-parietal and ventromedial frontal cortex), cerebellar network, sensorimotor network (supplementary motor area, sensorimotor cortex and secondary somatosensory cortex), auditory network (superior temporal gyrus, Heschl's gyrus and posterior insular), executive control network (medial-frontal areas, including anterior cingulate and paracingulate) and two frontoparietal networks (frontoparietal areas left and right). With the dual regression method, spatial maps representing voxel-to-network connectivity were estimated for each dataset separately in two stages for use in


within-group comparisons. First, the weighted network maps were simultaneously used in a spatial regression into each dataset. This stage generated 12 time series per dataset that describe the average temporal course of signal fluctuations of the 10 networks plus 2 confound regressors (cerebrospinal fluid and white matter). Next, this combination of time series was entered in a temporal regression into the same dataset. This resulted in a spatial map per network per dataset with regression coefficients referring to the weight of each voxel being associated with the characteristic signal change of a specific network. The higher the value of the coefficient, the stronger the connectivity of this voxel with a given network. These individual statistical maps were subsequently used for higher level analysis.

To infer treatment effects of citalopram and galantamine vs. placebo across time as well as for each time point separately we used non-parametric combination (NPC) as provided by FSL's Permutation Analysis for Linear Models tool (PALM vs65-alpha) [209, 210]. NPC is a multivariate method that offers the possibility to combine data of separate, possibly non-independent tests, such as our multiple time points, and investigate the presence of joint effects across time points, in a test that has fewer assumptions and is more powerful than repeated-measurements analysis of variance (ANOVA) or multivariate analysis of variance (MANOVA). NPC testing was used in two phases to estimate for each network whether connectivity was significantly different on drug relative to placebo days. First, tests were performed for each time point using 5000 synchronized permutations. More specifically, to investigate changes in voxelwise functional connectivity with each of the 10 functional networks, four t-tests (drug vs. placebo) were performed for all post-dose time points ( $T = 2.5, 3.5, 4.5$  and  $6$  h), with average heart rate (beats/m) per RS-fMRI scan as confound regressor [127]. The average of the two baseline RS-fMRI scans was used as covariate as well, by adding the coefficient spatial map as a voxel-dependent regressor in the model. Second, tests for the four time points were combined non-parametrically via NPC using Fisher's combining function [211] and the same set of synchronized permutations as mentioned above. Threshold-free cluster enhancement was applied to the tests at each time point and after the combination, and the resulting voxelwise statistical maps were corrected for the familywise error rate using the distribution of the maximum statistic [128, 129]. Voxels were considered significant at  $p$ -values  $< 0.05$ , corrected.

## RESULTS

### Pharmacokinetics

The time to reach maximum plasma concentrations ( $T_{max}$ ) was highly variable for both citalopram and galantamine (see Figure 3.2 for individual and median PK time profiles). Maximum plasma concentrations of citalopram were reached between 1.93 and 6 h after the first dose (mean  $T_{max}$ :  $2.99 \pm 1.18$ ) and between 2.48 and 6.05 h (mean  $T_{max}$ :  $4.92 \pm 1.33$ ) for desmethylcitalopram.



**Figure 3.2.** Median (bold line) and individual (thin lines) pharmacokinetic profiles for citalopram (left) and galantamine (right) concentrations in nanograms per milliliter on semi-log scale. Grey bars illustrate moments of RS-fMRI acquisition post drug administration. Observations below limit of quantification were dismissed.


$C_{max}$  for citalopram was between 20.4 and 42.4 ng/mL (mean  $C_{max}$ :  $35.8 \pm 6.34$ ) and between 1.45 and 4.7 ng/mL (mean  $C_{max}$ :  $2.95 \pm 1.07$ ) for desmethylcitalopram.  $AUC_{0-last}$  was between 86.8 and 186 ng\*h/mL (mean  $AUC_{0-last}$ :  $146 \pm 25.2$ ) for citalopram and between 5.43 and 18.6 ng\*h/mL (mean  $AUC_{0-last}$ :  $11.7 \pm 4.78$ ) for desmethylcitalopram. Maximum plasma concentrations of galantamine were reached between 0.5 and 4 h (mean  $T_{max}$ :  $2.67 \pm 1.11$ ). Consequently, maximum concentrations were reached between 2.5 and 6 h post zero point (mean  $T_{max}$ :  $4.67 \pm 1.11$ ).  $C_{max}$  for galantamine was between 25.6 and 61.4 ng/mL (mean  $C_{max}$ :  $40.7 \pm 10.4$ ).  $AUC_{0-last}$  was between 49.1 and 152 ng\*h/mL (mean  $AUC_{0-last}$ :  $95.1 \pm 27.7$ ).

### Cortisol and prolactin

As shown in Figure 3.3a/b, concentrations of cortisol and prolactin increased after citalopram, relative to placebo ( $p < 0.01$ ). There was no significant treatment effect of galantamine on either neuroendocrine hormone concentration.

### NeuroCart® test battery

There were no significant treatment effects of citalopram and galantamine on measures of cognitive performance. Compared with placebo, galantamine increased the level of nausea as measured with the VAS Nausea ( $p < 0.05$ ). Citalopram did not cause significant nausea (see Figure 3.3c). The effects of citalopram and galantamine on all cognitive and subjective NeuroCart® measures are summarized in Supplementary Table S3.1.



**Figure 3.3.** Least squares means percent change from baseline profiles of cortisol and prolactin concentrations and nausea as measured with the Visual Analogue Scales (with standard errors of the mean as error bars).

## Imaging

### *Citalopram: combined test*

Combining the data of all post-dose time points, there was a decrease in connectivity after administering citalopram compared with placebo (Figure 3.4a) between (1) the sensorimotor network and the pre- and postcentral gyri, supplementary motor area (SMA), precuneus, posterior and anterior cingulate cortex (PCC/ACC), medial prefrontal cortex and cerebellum, and (2) the right frontoparietal network and brain stem.

### *Citalopram: partial tests*

Time specific effects of citalopram compared with placebo were explored by investigating changes in connectivity for each partial test (each time point post dosing) that contributed to the combined test (see Figure 3.4b).

At T = 2.5 h after citalopram administration there were no significant changes in connectivity.

At T = 3.5 h after citalopram administration there was a decrease in connectivity between the right frontoparietal network and the insula and Heschl's gyrus.

At T = 4.5 h after citalopram administration there was a decrease in connectivity between (1) the default mode network and the precuneus, PCC, ACC, cerebellum and left temporal lobe, (2) the sensorimotor network and the pre- and postcentral gyri, SMA, precuneus, PCC, ACC, medial prefrontal cortex, planum temporale and Heschl's gyrus, and (3) the right frontoparietal network and brain stem.

At T = 6 h after citalopram administration there was a decrease in connectivity between the executive control network and the middle and superior frontal gyrus.


Specifications of citalopram's combined and partial effects (sizes of significant regions and peak z-values) are provided in Table 3.1.

### *Galantamine: combined test*


Combining the data of all post-dose time points, there was an increase in connectivity after administering galantamine compared with placebo (Figure 3.5a) between visual network 2 (occipital pole) and the left and right hippocampus, precuneus, thalamus, fusiform gyrus, precentral and superior frontal gyrus, PCC and cerebellum.

### *Galantamine: partial tests*

Time specific effects of galantamine compared with placebo were explored by investigating changes in connectivity for each partial test (each time point post dosing) that contributed to the combined test (see Figure 3.5b).



**Figure 3.4.** Statistical maps of citalopram induced decreases in functional connectivity. Networks are shown in green with decreases in connectivity with the network in blue (at  $p < 0.05$ , corrected). Figure (a) shows significant alterations in connectivity for all time points post dosing combined (with coordinates in mm). Figure (b) shows significant alterations in connectivity for each time point separately. Plots visualize the corresponding average time profiles of changes in functional connectivity for citalopram (dotted line) and placebo (continuous line) conditions (z-values with standard errors of the mean as error bars). Coronal and axial slices are displayed in radiological convention (left = right).



**Figure 3.5.** Statistical maps of galantamine induced increases and decreases in functional connectivity. Networks are shown in green with increases in connectivity with the network in red and decreases in connectivity in blue (at  $p < 0.05$ , corrected). Figure (a) shows significant alterations in connectivity for all time points post dosing combined (with coordinates in mm). Figure (b) shows significant alterations in connectivity for each time point separately. Plots visualize the corresponding average time profiles of changes in functional connectivity for galantamine (dotted line) and placebo (continuous line) conditions (z-values with standard errors of the mean as error bars). Coronal and axial slices are displayed in radiological convention (left = right).

**Table 3.1.** Overview of significant decreases in functional connectivity after citalopram as estimated with threshold-free cluster enhancement ( $p < 0.05$ , corrected)

Network	NPC/T	Region (Harvard-Oxford)	z*	x	y	z	# voxels
<b>Sensorimotor network</b>	NPC	L/R/M ACC, PCC, precuneus, SMA, post- and precentral gyrus, medial and orbital frontal cortex	5.23	-22	50	-16	27308
		L/R/M Cerebellum	4.28	0	-72	-30	1696
	R/M	L/M Lateral occipital cortex, inferior and superior division	4.20	-14	-92	20	585
		R Cerebellum and temporal occipital fusiform cortex	3.92	36	-78	-22	530
<b>Sensorimotor network</b>	L	R/M Occipital pole and lingual gyrus	3.28	8	-96	-6	92
		L Superior frontal gyrus	3.25	-18	32	28	91
		L/R/M ACC, PCC, precuneus, SMA, brain stem, post- and precentral gyrus, orbital frontal cortex and cerebellum, lateral occipital cortex, inferior and superior division	5.03	-14	-92	20	46242
	L	L Insular cortex, temporal and frontal opercular cortex	4.91	-38	16	-4	498
<b>Frontoparietal network right</b>	M	M Thalamus	4.72	2	-12	18	212
		M Brain stem	4.42	2	-26	-16	55
<b>Frontoparietal network right</b>	R	R T = 3.5 Insular and central opercular cortex	5.22	40	4	4	41
		R Insular cortex and Heschl's gyrus	4.53	40	-16	4	11
<b>Frontoparietal network right</b>	L/R/M	L Brain stem and cerebellum	4.43	8	-44	-18	1655
		L Frontal orbital cortex	3.72	-26	8	-14	45
		L Parietal opercular cortex	3.78	-32	-44	28	34
<b>Default mode network</b>	L/R	L T = 4.5 Cerebellum	5.14	-22	-78	-24	5374
		L/M Precuneus, PCC, hippocampus, temporal and supramarginal gyrus	4.56	-36	-58	28	2407
		L Lateral occipital cortex, inferior and superior division	4.40	-28	-82	8	134
<b>Executive control network</b>	R	R T = 6 Precentral gyrus, inferior and middle frontal gyrus	4.63	42	16	20	302
		R Superior and middle frontal gyrus	4.48	28	2	58	213
		R Lateral occipital cortex, inferior and superior division	3.91	56	-70	-4	187
		R Inferior temporal gyrus	4.07	54	-44	-24	37
		R Parietal operculum cortex	5.21	36	-36	20	19
R	R Precentral gyrus	4.18	42	0	32	15	

Abbreviations: L = left, R = right, M = midline, ACC = anterior cingulate cortex, PCC = posterior cingulate cortex, SMA = supplementary motor area. Voxel dimension = 2 mm x 2 mm x 2 mm (voxel volume 0.008 mL). \* = standardized z-value of the uncorrected peak Fisher- (NPC) or t-statistic (partial tests) within regions.



At T = 2.5 h after galantamine administration there was a decrease in connectivity between the default mode network and precuneus, PCC and calcarine cortex.

At T = 3.5 h after galantamine administration there was (1) a decrease in connectivity between visual network 1 (medial visual areas) and the right hippocampus, PCC and ACC, and (2) an increase in connectivity between visual network 2 (occipital pole) and the cerebellum.

At T = 4.5 h after galantamine administration there was a decrease in connectivity between the left frontoparietal network and the medial prefrontal cortex, precuneus, PCC and ACC.

At T = 6 h after galantamine administration there was an increase in connectivity between (1) visual network 2 (occipital pole) and the hippocampus, brain stem, cerebellum and fusiform cortex, and (2) the auditory network and PCC, precuneus, and pre- and postcentral gyri.

Specifications of galantamine's combined and partial effects (sizes of significant regions and peak z-values) are provided in Table 3.2.

## DISCUSSION

Single-dose SSRI and AChEI administration is usually not sufficient to alter cognitive and behavioral states in depression or dementia [167, 212-215]. Pharmacological research and development is therefore often restricted to clinical trials that last for weeks or even months. However, considering the acute elevations of synaptic neurotransmitters, it is expected that changes will already take place on a neural level, well before this results in improved performance and clinical outcome. In our study, both agents altered resting state functional connectivity within our time frame of measurements. The results of our study replicate the finding that SSRIs can have an immediate and widespread diminishing impact on interactions of the healthy neural system [83, 171, 199]. In conjunction with other SSRIs, citalopram had clear neuroendocrine effects [216], but did not induce cognitive or subjective changes as measured with the NeuroCart® battery. Network effects of galantamine were more discrete and variable over time. The relatively low dose and highly variable PK properties of this drug in our study and an unexpected delay in onset of galantamine's  $T_{max}$  which may in hindsight be related to a food interaction with lunch, may have obscured the detection of more subtle fMRI effects and time-related changes. Galantamine increased nausea but did not alter cognitive or behavioral states.

### Citalopram

In congruence with both task-related [171, 217] and resting-state fMRI paradigms with SSRIs [83, 199], citalopram rapidly lowered connectivity in several cortical and subcortical regions. This

**Table 3.2.** Overview of significant decreases (↓) and increases (↑) in functional connectivity after galantamine as estimated with threshold-free cluster enhancement ( $p < 0.05$ , corrected)

Network	NPC/T	Region (Harvard-Oxford)	z*	x	y	z	# voxels	
<b>Visual network 2 (↑)</b>	NPC	L/R/M	4.84	2	-62	-26	10765	
		Hippocampus, thalamus, precuneus, PCC, lateral occipital cortex, brain stem, fusiform gyrus, superior frontal gyrus, precentral gyrus and cerebellum						
		L/M	4.21	8	-48	-44	1249	
		M	3.10	-8	-40	54	147	
		R	4.09	34	32	0	31	
<b>Default mode network (↓)</b>	T = 2.5	R	3.56	48	14	14	25	
		R	3.40	50	10	-2	16	
		R/M	4.36	10	-58	26	210	
		R	4.34	40	-72	28	74	
		M	3.70	4	-54	2	15	
<b>Visual network 1 (↓)</b>	T = 3.5	M	4.41	8	22	18	246	
		R	3.64	14	-56	16	210	
		R	4.06	48	-26	0	105	
		R/M	3.65	14	8	38	93	
		L	3.46	-18	-46	-12	91	
<b>Visual network 2 (↑)</b>	T = 3.5	R	4.54	18	2	-8	76	
		R	4.79	24	-66	-36	14	
		R						

Table 3.2 continues on next page

Table 3.2. Continued

Network	NPC/T	Region (Harvard-Oxford)	z*	x	y	z	# voxels	
<b>Visual network 2 (†)</b>	T = 6	L/R/M	5.01	8	-48	-44	4876	
		Hippocampus, parahippocampal gyrus, cerebellum, brain stem, temporal occipital fusiform cortex and inferior temporal gyrus						
		R	4.24	28	-62	52	677	
		R	3.85	32	-8	38	470	
		R	4.32	14	-24	44	372	
<b>Frontoparietal network left (‡)</b>	T = 4.5	L	3.66	-18	-68	52	152	
		R	3.62	42	-76	30	146	
		L/R/M	5.25	-2	52	-2	630	
<b>Auditory network (†)</b>	T = 6	R	4.12	16	-50	12	110	
		R	4.53	12	-30	-16	44	
		R	3.44	36	-42	-10	14	
		L/M	4.83	-4	-32	48	188	
		L	4.65	-46	-28	50	23	

Abbreviations: L = left, R = right, M = midline, ACC = anterior cingulate cortex, PCC = posterior cingulate cortex. Voxel dimension = 2 mm x 2 mm x 2 mm (voxel volume 0.008 mL). \* = standardized z-value of the uncorrected peak Fisher- (NPC) or t-statistic (partial tests) within regions.

is consistent with the numerous afferent and efferent serotonergic fibers originating from the brain stem's raphe nuclei [218]. Compared with our recent results on the SSRI sertraline [199], there was considerable overlap between the two SSRIs in direction (decreased connectivity) and regions (ACC, PCC, precuneus, prefrontal cortex, midbrain and motor cortex) of effect, especially with respect to other pharmacological compounds that usually show more restricted responses [76, 78, 80]. Part of these findings is in line with RS-fMRI studies in depressed patients who exhibit hyperconnectivity of cortical midline structures (ACC, PCC, precuneus and medial prefrontal regions) that are related to emotion regulation and modulated by serotonin transmission [88, 219]. It has been hypothesized that this increase in connectivity in depression is representative of disruptions in self-consciousness and rumination of negative thoughts [142, 144]. An explanation of the overall inhibitory effect of acute SSRI exposure is the relative predominance of inhibitory 5-HT<sub>1</sub> vs. stimulatory 5-HT<sub>2</sub> receptor subtypes [133] that has been demonstrated throughout the cortex [110, 132, 151, 152]. Most outstanding was the citalopram induced decrease in connectivity with the sensorimotor network, mainly due to alterations at T = 4.5 h. Citalopram also increased cortisol and prolactin levels, most noticeable at one time point as well (T = 2.5 h for cortisol and T = 3.5 h for prolactin). Although this took place before appearance of the largest alterations in connectivity, it postulates an apex in the pharmacodynamic effect of citalopram. Equal SSRI effects for the sensorimotor network (decreased connectivity with the sensorimotor region, supplementary motor area, precuneus and cingulate cortex) have been found earlier [199]. The primary motor and somatosensory cortex are both characterized by a high 5-HT axon density [220] and serotonin is recognized to be important for motor behavior in animals and humans [221, 222]. This is demonstrated by enhanced motor area activity during improved motor performance after SSRI administration [155, 156]. The precuneus and cingulate cortex are presumed to support voluntary and complex motor control [157, 159] and seem to play a central role in SSRI enhancement [199]. While the effect was more focal, connectivity between the midbrain and right fronto-parietal network was decreased as well. This matches observations that acute blockade of serotonin reuptake activates 5-HT<sub>1A</sub> autoreceptors in the midbrain's median and dorsal raphe nuclei [47, 109, 134], in turn leading to reduced 5-HT release in particularly the forebrain [130, 223].

Nevertheless, comparing effects of citalopram and sertraline, we did not find alterations in relation to exact identical functional networks. No differences have been found on the antidepressant efficacy of both SSRIs [224, 225], although sertraline induces more gastrointestinal side effects than citalopram [224, 225]. This corresponds to our finding that sertraline significantly increased the level of nausea, whereas this did not occur in our current study group. Citalopram is also known as the most selective SSRI; sertraline has more affinity for dopamine, noradrenaline and  $\sigma$ -receptors than citalopram [180], which in turn modulate N-methyl-D-aspartate and glutamate receptors as well [226]. Citalopram, on the other hand, has a high affinity on histamine H<sub>1</sub> receptors [180]. It is possible that these properties may account for differences in network

changes between the two SSRIs [81, 227]. However, it is yet to be established what the value is of specific network vs. region effects in connectivity analyses. Considering the resemblance in direction and location of effect we presume that sertraline and citalopram induce quite comparable connectivity alterations.

### **Galantamine**

The cholinergic system is mostly related to aging and aging related diseases, as cholinergic malfunction, especially in the hippocampus, cortex, the entorhinal area, the ventral striatum, and the basal forebrain, plays a key role in associated functional degeneration [228, 229]. Combining fMRI data of all time points, we found an increase in connectivity with the visual network which was mostly associated with effects on T = 6 h. The medial and lateral cholinergic pathways, originating from Meynert's basal nucleus, supply a large portion of the brain and merge in the posterior occipital lobe [230]. In dementia and schizophrenia, it is hypothesized that cholinergic dysregulation is responsible for psychotic manifestations and AChEIs have been successfully used for treatment of visual hallucinations [231, 232]. ACh release in the primary visual cortex is increased during visual stimulation pointing to ACh as influencing visual processing and learning mechanisms [233, 234]. It has been proposed that cholinergic enhancement facilitates bottom-up visual attention and perception by increasing activity in the extrastriate cortex [235, 236]. More importantly, galantamine altered connectivity with areas that are highly relevant in learning and memory: the left and right hippocampus and thalamus. Changes in cholinergic markers such as choline acetyltransferase, acetylcholinesterase and muscarinic and nicotinic acetylcholine receptor availability in hippocampal regions is typical for AD and normal aging [229]. In patients with AD, hippocampal volume loss appears to slow down during treatment with donepezil [237] and cholinergic enhancement even improved visual and verbal episodic memory and long-term visual episodic recall in healthy young subjects, memory domains that are specifically related to hippocampal functioning [238]. Cholinergic treatment aided the processing of novel faces in AD patients, which was accompanied by normalization in the fusiform gyrus [239, 240], where we found connectivity changes as well. In addition, acute exposure to cholinergic stimulation increased activation in occipital and hippocampal regions of patients with AD and mild cognitive impairment (MCI) during a visual memory task [241, 242]. The thalamus, considered to be a gate for sensory information, contains various nuclei that receive excitatory cholinergic input [243], including the lateral geniculate nucleus that has feedback connections with the primary visual cortex [244, 245]. Results for this network are compatible with previous studies [246, 247], indicating that cholinergic enhancement benefits memory performance and visual stimulation orientation by selective perceptual processing.

## Repeated measures

Collecting multiple scans per day increases the power of the statistical test and decreases individual variability, which reduces the need for large sample sizes. The observed variation in connectivity on placebo days emphasizes the importance of a placebo-controlled design with repeated measures, providing insight into potential diurnal fluctuations. Furthermore, it offers possibilities to investigate effects on different time points and relate these effects to other pharmacodynamic and PK profiles. NPC groups the data of all time points to test one joint null hypothesis without the necessity to explicitly model their dependence [209, 210], ending up with effects among them that are statistically most robust. In addition, univariate partial tests allow for inference per time point. For citalopram, it might have been sufficient to acquire scans at one time point ( $T = 4.5$  h). However, it is largely impossible to predict beforehand at which specific moment we can expect the most stable and 'real' drug effect, since the peak effect does not appear to coincide directly with the observed  $T_{\max}$  in plasma and neuroendocrine responses. Effects at other time points may not reach significance but still contribute to the net result. The combined outcome therefore tends to be more reliable and powerful in defining pharmacological effects that are variable over time, as it will grasp the strongest effects without the risk of missing out on important information [211]. This does not imply that the partial (time specific) effects are meaningless. A decrease in connectivity at  $T = 4.5$  h between the default mode network and precuneus, PCC and ACC is in line with earlier results [82, 85-87, 199] and in agreement with opposite features in depression, which is characterized by increased connectivity of DMN components [88]. Especially the posterior part of the DMN, where citalopram effects were most prevalent, has been implicated in SSRI efficacy in depression [84, 145]. Furthermore, consistent with an increased cerebellar-DMN connectivity in depression [88], citalopram reduced connectivity between the DMN and cerebellum. The cerebellum is primarily known for its service in motor control, illustrating our findings for the sensorimotor network, but influences mood regulation as well [248, 249].

In contrast to citalopram, the effects of galantamine were more focal, less related to a specific network or point in time and less uniform with regard to direction of effect. This heterogeneity in effect possibly reflects the large kinetic variability in this study. Although the variation in timing of  $T_{\max}$  did not clearly differ between citalopram and galantamine, the variance of galantamine's  $C_{\max}$  (ranging from 25.6 to 61.4 ng/mL) was high compared with citalopram and desmethylcitalopram. Since the combined effect mainly depended on the last time point it is possible that the impact of galantamine does not follow a time course that equals the PK profile or that effects might have become larger and more stable later in time. This is congruent with the unanticipated delay in onset of galantamine's  $T_{\max}$  in our study group, resulting in a less powerful aggregation of data, in which especially the value of measurements at  $T = 2.5$  is questionable. Although galantamine is known for a  $T_{\max}$  of 1-2 h after dosing, the mean  $T_{\max}$  in our sample was 2.67 h (4.67 h after zero point), whereas citalopram, known for a  $T_{\max}$  between 2 and 4 h, did reach its maximum

concentration at 2.99 h post dosing. Furthermore, the relatively low dose and variable kinetic time profile of galantamine might have contributed to the absence of a larger response on functional connectivity and neuroendocrine parameters. A larger sample size, a higher dose of galantamine (16-32 mg), and earlier drug administration might have reduced this variability in response. The outcomes of our partial tests reveal additional information beyond the combined approach as well. There is a tendency towards diminished DMN activity in normal aging, MCI and dementia, pointing to reduced integrity of structures that are vulnerable to atrophy, beta amyloid deposition and reduced glucose metabolism [20]. Studies that are performed on the resting state fMRI response to cholinergic interventions are restricted to AD patients and mainly indicate an increase in connectivity with DMN areas [89-91]. In another study, no effect on the DMN was found in both APOE  $\epsilon 4$  carriers and non-carriers [200]. Acute exposure to cholinergic stimulation decreased DMN connectivity with the precuneus and occipital cortex in our study group at T = 2.5 h. This direction of effect might be the consequence of investigating cholinergic responses in healthy young adults instead of subjects with impaired cholinergic systems. It is possible that when neural cholinergic processes are still intact, ceiling effects may prevent further activation and excessive stimulation may actually impair optimal connectivity. Moreover, these studies all used AChEI treatment for several weeks, instead of our single-dose administration. More research is needed to unravel differential cholinergic responses among specific populations and treatment designs.

### Limitations

Agents that enhance the cholinergic and serotonergic system commonly elicit gastrointestinal adverse events, which is attributable to their peripheral influences [250, 251]. In order to prevent these adverse effects, we administered granisetron on both drug- and placebo study days before study drug administration. RS-fMRI effects of selective 5-HT<sub>3</sub> receptor antagonists as granisetron are lacking, but need to be taken into consideration when interpreting the results [109]. However, intolerance to our intensive study procedures would have been undesirable [181] and vomiting might have altered brain connectivity as well. To reduce nausea, we also decided to administer citalopram in two doses, and to skip the second dose in case of tolerability issues. For citalopram, our measures were adequate, and all subjects received both doses without significant nausea. For the same reasons, a relatively low dose of galantamine was chosen. However, increased nausea was present after administering galantamine compared with placebo, primarily at the end of the day, which may also have influenced some of the observed network effects but justifies our decision to limit the dose of galantamine. This also emphasizes the mismatch of our repeated measurements and galantamine's absorption rate. Despite our attempt to equalize the PK responses of citalopram and galantamine during the course of the day, both drugs did not reach their maximum concentration at the same time point, which hampers comparability. Currently, no accepted methods are available to include individual drug concentrations in the

network analysis. Further, fMRI effects, especially in pharmacological research, are potentially the result of vasodilation, and hence to changes in neurovascular coupling instead of true neural activity [185, 186]. Although SSRIs do not typically alter the hemodynamic response [188], AChEIs could increase vessel tone by contraction of the smooth muscles of blood vessels [252, 253]. Yet, there was no significant treatment effect of either drug on heart rate frequency, which minimizes the probability of cardiac artifacts. Besides, vessel dilation would more likely alter connections throughout the entire brain instead of inducing the network-specific effects that we observed. Future studies with appropriate protocols are needed to specify these processes more accurately.

### **Summary**

This study provides further support for RS-fMRI as a sensitive method for investigating instant neural processes after pharmacological challenges. The results on the SSRI citalopram and AChEI galantamine identify their neuromodulating role in cognitive and sensory systems. Citalopram altered connectivity with networks and regions that are mostly implied in sensorimotor functioning and self-reference, whereas the results of galantamine show acetylcholine's relation to visual processing and learning mechanisms. Our findings also encourage the use of repeated measurements after single-dose administration, leading to a more powerful and reliable picture of pharmacological effects. Results may have been partially obscured by the variability of individual PK characteristics, which was larger than expected. A future challenge therefore is to develop appropriate statistical models (PK/PD-modeling) to investigate concentration-dependent modulation of resting state functional connectivity.

### **Acknowledgements**

Erica S. Klaassen and Jasper Stevens (CHDR) are acknowledged for their contribution to statistical analyses.



Supplementary Table S3.1: Summary of treatment effects of citalopram and galantamine on the NeuroCart® cognitive test battery

Parameter	Least Squares Means			Treatment p-value			Contrasts		
	Placebo	Citalopram	Galantamine	Placebo	Citalopram vs. placebo	Galantamine vs. placebo	Placebo	Galantamine vs. placebo	Citalopram vs. galantamine
VAS Alertness (mm)	49.3	48.3	47.3	0.329	-0.9 (-3.7, 1.8) <i>p</i> = 0.485	-2.0 (-4.6, 0.7) <i>p</i> = 0.141	1.0 (-1.7, 3.7) <i>p</i> = 0.443		
VAS Calmness (mm)	52.9	51.5	52.9	0.326	-1.4 (-3.7, 0.9) <i>p</i> = 0.217	0.0 (-2.3, 2.4) <i>p</i> = 0.976	-1.4 (-3.6, 0.8) <i>p</i> = 0.188		
VAS Mood (mm)	53.5	51.2	52.3	0.169	-2.3 (-4.7, 0.1) <i>p</i> = 0.063 <sup>2</sup>	-1.2 (-3.7, 1.2) <i>p</i> = 0.310	-1.1 (-3.5, 1.3) <i>p</i> = 0.359		
VAS Nausea log (mm)	0.32	0.37	0.49	0.084	0.048 (-0.104, 0.200) <i>p</i> = 0.519	<b>0.169 (0.015, 0.323) <i>p</i> = 0.033<sup>1</sup></b>	-1.21 (-2.72, 0.030) <i>p</i> = 0.109		
Adaptive tracking (%)	24.7	23.4	23.4	0.219	-1.32 (-3.09, 0.46) <i>p</i> = 0.137	-1.34 (-3.11, 0.43) <i>p</i> = 0.129	0.02 (-1.75, 1.80) <i>p</i> = 0.977		
Simple reaction time task (s)	265.16	275.04	268.09	0.265	3.7% (-1.0%, 8.7%) <i>p</i> = 0.117	1.1% (-3.5%, 5.9%) <i>p</i> = 0.627	2.6% (-2.1%, 7.5%) <i>p</i> = 0.264		
Stroop mean RT Incongruent-Congruent (ms)	62.2	85.4	69.9	0.433	23.2 (-14.6, 61.0) <i>p</i> = 0.214	7.7 (-30.4, 45.8) <i>p</i> = 0.678	15.5 (-21.2, 52.2) <i>p</i> = 0.387		
Stroop Correct Congruent-Incongruent	0.1	0.3	0.1	0.573	0.2 (-0.3, 0.6) <i>p</i> = 0.444	-0.0 (-0.5, 0.4) <i>p</i> = 0.830	0.2 (-0.2, 0.7) <i>p</i> = 0.318		
SDST Correct Responses	63.3	63.1	63.1	0.762	-0.2 (-0.8, 0.4) <i>p</i> = 0.517	-0.2 (-0.8, 0.4) <i>p</i> = 0.553	-0.0 (-0.7, 0.6) <i>p</i> = 0.928		
SDST Average Reaction Time (ms)	1468.53	1541.28	1538.40	0.093	72.75 (-1.60, 147.1) <i>p</i> = 0.055 <sup>2</sup>	69.87 (-4.50, 144.2) <i>p</i> = 0.064 <sup>2</sup>	2.88 (-71.5, 77.25) <i>p</i> = 0.935		
N-back mean RT 0 back (ms)	401	403	394	0.654	2 (-19, 23) <i>p</i> = 0.838	-7 (-29, 15) <i>p</i> = 0.497	9 (-13, 31) <i>p</i> = 0.384		
N-back mean RT 1 back (ms)	432	431	416	0.266	-1 (-22, 21) <i>p</i> = 0.930	-15 (-37, 6) <i>p</i> = 0.152	14 (-7, 36) <i>p</i> = 0.173		
N-back mean RT 2 back (ms)	510	517	504	0.832	7 (-37, 51) <i>p</i> = 0.732	-5 (-49, 39) <i>p</i> = 0.797	13 (-31, 57) <i>p</i> = 0.551		
N-back correct:incorrect/total 0 back	0.95	0.96	0.95	0.812	0.01 (-0.03, 0.05) <i>p</i> = 0.602	-0.00 (-0.04, 0.04) <i>p</i> = 0.956	0.01 (-0.03, 0.05) <i>p</i> = 0.564		
N-back correct:incorrect/total 1 back	0.96	0.96	0.95	0.583	0.00 (-0.04, 0.05) <i>p</i> = 0.895	-0.02 (-0.06, 0.03) <i>p</i> = 0.422	0.02 (-0.02, 0.06) <i>p</i> = 0.345		
N-back correct:incorrect/total 2 back	0.92	0.91	0.92	0.913	-0.01 (-0.06, 0.04) <i>p</i> = 0.719	0.00 (-0.05, 0.05) <i>p</i> = 0.997	-0.01 (-0.06, 0.04) <i>p</i> = 0.709		
WLT Recall 1 correct	11.4	10.7	12	0.484	-0.8 (-3.0, 1.5) <i>p</i> = 0.499	0.6 (-1.7, 2.9) <i>p</i> = 0.598	-1.3 (-3.6, 0.9) <i>p</i> = 0.235		
WLT Recall 2 correct	16.9	16.8	16.8	0.993	-0.1 (-1.8, 1.6) <i>p</i> = 0.920	-0.1 (-1.8, 1.6) <i>p</i> = 0.920	-0.0 (-1.7, 1.7) <i>p</i> = 1.000		
WLT Recall 3 correct	19.8	19.9	19.6	0.944	0.1 (-2.1, 2.2) <i>p</i> = 0.936	-0.2 (-2.4, 1.9) <i>p</i> = 0.809	0.3 (-1.8, 2.5) <i>p</i> = 0.748		
WLT Delayed Recall correct	18.4	17.0	18.1	0.329	-1.4 (-3.4, 0.6) <i>p</i> = 0.158	-0.3 (-2.3, 1.7) <i>p</i> = 0.734	-1.1 (-3.1, 0.9) <i>p</i> = 0.275		
WLT Delayed Recognition correct	25.7	26.2	26.9	0.506	0.6 (-1.6, 2.8) <i>p</i> = 0.586	1.3 (-0.9, 3.4) <i>p</i> = 0.249	-0.7 (-2.9, 1.5) <i>p</i> = 0.534		
WLT Delayed Recognition RT correct (ms)	894.3	860.8	836.3	0.241	-33.6 (-103, 35.9) <i>p</i> = 0.326	-58.0 (-128, 11.5) <i>p</i> = 0.097 <sup>2</sup>	24.4 (-45.1, 93.9) <i>p</i> = 0.472		

Abbreviations: VAS = Visual Analogue Scale; SDST: Symbol Digit Substitution Test; WLT = Visual Verbal Learning Test; RT = reaction time. <sup>1</sup>Significant at *p* < 0.05; <sup>2</sup>non-significant trend (0.05 < *p* < 1.0).

